| Assessment Status |
Awaiting response from Applicant |
| HTA ID |
22050 |
| Drug |
Trastuzumab deruxtecan |
| Brand |
Enhertu® |
| Indication |
As monotherapy for the treatment of adult patients with unresectable or metastatic HER2-positive breast cancer who have received one or more prior anti-HER2-based regimens. |
| Rapid review commissioned |
11/07/2022 |
| Rapid review completed |
27/07/2022 |
| Rapid review outcome |
A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of trastuzumab deruxtecan compared with the current standard of care. |
| Full pharmacoeconomic assessment commissioned by HSE |
31/08/2022 |
| Pre-submission consultation with Applicant |
25/10/2022 |
| Full submission received from Applicant |
09/03/2023 |
| Preliminary review sent to Applicant |
15/09/2023 |
